The estimated Net Worth of H Stewart Parker is at least $245 mil dollars as of 1 June 2022. Ms. Parker owns over 5,000 units of Sangamo Therapeutics Inc stock worth over $40,908 and over the last 10 years she sold SGMO stock worth over $0. In addition, she makes $203,812 as Independent Director at Sangamo Therapeutics Inc.
H has made over 4 trades of the Sangamo Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she bought 5,000 units of SGMO stock worth $18,000 on 1 June 2022.
The largest trade she's ever made was buying 5,000 units of Sangamo Therapeutics Inc stock on 1 June 2022 worth over $18,000. On average, H trades about 522 units every 59 days since 2014. As of 1 June 2022 she still owns at least 48,700 units of Sangamo Therapeutics Inc stock.
You can see the complete history of Ms. Parker stock trades at the bottom of the page.
H. Stewart Parker is Independent Director of the Company. Ms. Parker has been a member of our Board of Directors since June 2014, and has been Chair since June 2017. Ms. Parker has over 30 years of experience in the biotechnology industry. Prior to focusing on boards and consulting, she served as the Chief Executive Officer of The Infectious Disease Research Institute (IDRI), a not-for-profit global health Research institute from March 2011 to December 2013. In 1992, Ms. Parker founded Targeted Genetics Corporation, a publicly traded Seattle-based biopharmaceutical company formed to develop gene-based treatments for acquired and inherited diseases that became a world leader in AAV gene therapy. She held the position of President and Chief Executive Officer and was a member of its board of directors from the company’s inception until November 2008. Prior to founding Targeted Genetics, Ms. Parker served in various capacities at Immunex from August 1981 through December 1991, most recently as Vice President, Corporate Development. From February 1991 to January 1993, Ms. Parker served as President and a Director of Receptech Corporation, a company formed by Immunex in 1989 to accelerate the development of soluble cytokine receptor products. She has served on the board of directors and the executive committee of BIO, the primary trade organization for the biotechnology industry. She currently serves on the board of directors of Armata Pharmaceuticals Inc. and Achieve Life Sciences, Inc. Ms. Parker received her B.A. and M.B.A. from the University of Washington. The Nominating and Corporate Governance Committee and the Board believe that Ms. Parker’s senior executive experience in AAV gene therapy and biotechnology drug development provides valuable operational, commercial assessment and management skills to the Board.
As the Independent Director of Sangamo Therapeutics Inc, the total compensation of H Parker at Sangamo Therapeutics Inc is $203,812. There are 8 executives at Sangamo Therapeutics Inc getting paid more, with Alexander Macrae having the highest compensation of $3,986,560.
H Parker is 64, she's been the Independent Director of Sangamo Therapeutics Inc since 2014. There are no older and 18 younger executives at Sangamo Therapeutics Inc.
H's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.
Over the last 24 years, insiders at Sangamo Therapeutics Inc have traded over $87,969,621 worth of Sangamo Therapeutics Inc stock and bought 3,434,008 units worth $48,483,268 . The most active insiders traders include Capital Management, L.P.Ra ..., Le Roy C Kopp, eInc.Biogen Ma Inc. Biogen. On average, Sangamo Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $40,671. The most recent stock trade was executed by Inc.Biogen Ma Inc. Biogen on 26 September 2023, trading 6,000,000 units of SGMO stock currently worth $3,000,000.
for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.
Sangamo Therapeutics Inc executives and other stock owners filed with the SEC include: